Rare diseases and effective treatments: Are we delivering?

The Lancet

Volumn 385, Issue 9970, 2015, Pages 750-752

  Luzzatto, Lucio ^a   Hollak, Carla E M ^b   Cox, Timothy M ^c   Schieppati, Arrigo ^d,e   Licht, Christoph ^f   Kääriäinen, Helena ^g   Merlini, Giampaolo ^h   Schaefer, Franz ⁱ   Simoens, Steven ^j   Pani, Luca ^k   Garattini, Silvio ^d   Remuzzi, Giuseppe ^d  

^a ISTITUTO TOSCANO TUMORI   (Italy)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^e Azienda Ospedaliera Papa Giovanni XXIII   (Italy)

^f HOSPITAL FOR SICK CHILDREN   (Canada)

^g European Platform for Patients' Organizations Science and Industry   (Belgium)

^h UNIVERSITY OF PAVIA   (Italy)

ⁱ UNIVERSITY OF HEIDELBERG   (Germany)

^j UNIVERSITY OF LEUVEN   (Belgium)

^k ITALIAN MEDICINES AGENCY   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ORPHAN DRUG;

CYSTIC FIBROSIS; DRUG COST; DRUG EFFICACY; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG MONITORING; EUROPEAN UNION; HEALTH SERVICE; HEPATITIS C; HUMAN; NOTE; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PRIORITY JOURNAL; RARE DISEASE; ECONOMICS; HEALTH CARE DELIVERY; LEGISLATION AND JURISPRUDENCE; MEDICATION COMPLIANCE; MOTIVATION; RARE DISEASES; STANDARDS;

DELIVERY OF HEALTH CARE; DRUG COSTS; DRUG INDUSTRY; HUMANS; MEDICATION ADHERENCE; MOTIVATION; ORPHAN DRUG PRODUCTION; RARE DISEASES;

EID: 84925581513     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(15)60297-5     Document Type: Note

References (10)

1. A Schieppati, JI Henter, E Daina, A Aperia Why rare diseases are an important medical and social issue Lancet 371 2008 2039 2041
2. Commission of the European Communities Communication on rare diseases: Europe's challenges COM(2008) 679 http://ec.europa.eu/health/ph-threats/non-com/docs/rare-com-en.pdf Nov 11, 2008 (accessed Jan 21, 2015)
3. Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products (consolidated version.7/8/2009) http://ec.europa.eu/health/files/eudralex/vol-1/reg-2000-141-cons-2009-07/reg-2000-141-cons-2009-07-en.pdf (accessed Jan 21, 2015)
4. P Hillmen, C Hall, JC Marsh et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria N Engl J Med 350 2004 552 559
5. C Parker Eculizumab for paroxysmal nocturnal haemoglobinuria Lancet 373 2009 759 767
6. CM Legendre, C Licht, P Muus et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome N Engl J Med 368 2013 2169 2181
7. BP O'Sullivan, DM Orenstein, CE Milla Pricing for orphan drugs: will the market bear what society cannot? JAMA 310 2013 1343 1344
8. E Picavet, L Annemans, I Cleemput, D Cassiman, S Simoens Market uptake of orphan drugs - a European analysis J Clin Pharm Ther 37 2012 664 667
9. HI Hyry, AD Stern, TM Cox, JC Roos Limits on use of health economic assessments for rare diseases QJM 107 2014 241 245
10. R Wyden, CE Grassley United States Senate Committee on Finance http://www.finance.senate.gov/imo/media/doc/Wyden-Grassley%20Document%20Request%20to%20Gilead%207-11-141.pdf July 11, 2014 (accessed Jan 21, 2015)